[HTML][HTML] Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria journal, 2018 - Springer
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - europepmc.org
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
[HTML][HTML] Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - malariajournal.biomedcentral.com
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
[HTML][HTML] Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - ncbi.nlm.nih.gov
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
J Baird, K Battle, R Howes - Malaria Journal, 2018 - ora.ox.ac.uk
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria journal, 2018 - pubmed.ncbi.nlm.nih.gov
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
JK Baird, KE Battle, RE Howes - 2018 - cabidigitallibrary.org
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - go.gale.com
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
[引用][C] Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - cir.nii.ac.jp
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of
G6PD deficiency and cytochrome P-450 2D6 polymorphisms | CiNii Research CiNii 国立情報学 …
G6PD deficiency and cytochrome P-450 2D6 polymorphisms | CiNii Research CiNii 国立情報学 …
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
JK Baird, KE Battle, RE Howes - Malaria Journal, 2018 - search.ebscohost.com
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …